Grifols signs 15-year immunoglobulin supply agreement with Canadian Blood Services

Grifols signed a 15-year agreement with Canadian Blood Services to manufacture immunoglobulin from Canadian plasma at its Montreal fractionation facility, aiming to increase Canada's Ig self-sufficiency from 15% to 50%. The deal includes an incremental 2.4 million grams of Ig annually.

“It's the first-ever agreement of its kind and will ensure Canadian plasma is processed into Ig medicines on Canadian soil for the exclusive needs of the thousands of patients in the country.”newswire.ca

• 1 source
• newswire.caGrifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for CanadaGrifolsSep 7, 2022

Summarized from public sources; check the original articles before acting on it.